Literature DB >> 34283341

Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy.

Ye Won Jeon1, Hyung Soon Park2,3, Yousun Ko4, Yu Sub Sung5,6, Byoung Yong Shim2, Young Jin Suh1, Hyun A Kim7.   

Abstract

BACKGROUND: Body composition, including sarcopenia and fat parameters, has received much attention as a prognostic factor in breast cancer.
METHODS: A total of 479 breast cancer patients who underwent surgery and received adjuvant chemotherapy were enrolled in this study. Body composition, including the index and density of skeletal muscle, visceral fat, subcutaneous fat, and intermuscular fat calculated by CT scan, was used as a prognostic factor. The endpoints were breast cancer-specific survival (BCSS) and overall survival (OS).
RESULTS: The number of patients with stages I, II, and III was 146 (30.5%), 237 (49.5%), and 96 (20%), respectively. Sarcopenia and muscle density were not significant prognostic factors for BCSS and OS. A high visceral fat index (VFI) was an independent prognostic factor for BCSS (HR, 2.55; 95% CI 1.10-5.95, p = 0.03) and OS (HR 2.55, 95% CI 1.26-5.16, p = 0.01). In addition, high intermuscular fat density (IMFD) was also a significant prognostic factor for BCSS (HR, 2.95; 95% CI 1.34-6.46, p = 0.007) and OS (HR 2.28, 95% CI 1.22-4.26, p = 0.01) in multivariate analysis.
CONCLUSION: VFI and IMFD were significant prognostic factors for BCSS and OS in breast cancer patients treated with adjuvant chemotherapy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Chemotherapy; Fat density; Survival; Visceral obesity

Year:  2021        PMID: 34283341     DOI: 10.1007/s10549-021-06322-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

Authors:  Bette J Caan; Elizabeth M Cespedes Feliciano; Carla M Prado; Stacey Alexeeff; Candyce H Kroenke; Patrick Bradshaw; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Taiwo A Olobatuyi; Wendy Y Chen
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

2.  Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review.

Authors:  Federica Rossi; Francesca Valdora; Bianca Bignotti; Lorenzo Torri; Giulia Succio; Alberto Stefano Tagliafico
Journal:  Cancer Treat Res Commun       Date:  2019-06-11

3.  Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.

Authors:  Eun Jin Song; Chan Wha Lee; So-Youn Jung; Byeong Nam Kim; Keun Seok Lee; Seeyoun Lee; Han-Sung Kang; In Hae Park; Moo Hyun Lee; Yun Ju Kim; Kyungran Ko; Sohee Kim; Byung-Ho Nam; Eun Sook Lee
Journal:  Breast Cancer Res Treat       Date:  2018-08-21       Impact factor: 4.872

4.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

5.  The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.

Authors:  Egidio Del Fabbro; Henrique Parsons; Carla L Warneke; Kalyan Pulivarthi; Jennifer K Litton; Rony Dev; Shana L Palla; Abenaa Brewster; Eduardo Bruera
Journal:  Oncologist       Date:  2012-08-17

6.  Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications.

Authors:  Norbert Stefan; Hans-Ulrich Häring; Frank B Hu; Matthias B Schulze
Journal:  Lancet Diabetes Endocrinol       Date:  2013-08-30       Impact factor: 32.069

Review 7.  Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies.

Authors:  D S M Chan; A R Vieira; D Aune; E V Bandera; D C Greenwood; A McTiernan; D Navarro Rosenblatt; I Thune; R Vieira; T Norat
Journal:  Ann Oncol       Date:  2014-04-27       Impact factor: 32.976

8.  Muscle mass as a target to reduce fatigue in patients with advanced cancer.

Authors:  Elisabeth C W Neefjes; Renske M van den Hurk; Susanne Blauwhoff-Buskermolen; Maurice J D L van der Vorst; Annemarie Becker-Commissaris; Marian A E de van der Schueren; Laurien M Buffart; Henk M W Verheul
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-06-21       Impact factor: 12.910

9.  Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.

Authors:  Ye Won Jeon; Su Hwan Kang; Min Ho Park; Woosung Lim; Se Heun Cho; Young Jin Suh
Journal:  BMC Cancer       Date:  2015-11-06       Impact factor: 4.430

10.  Prognostic Value of Skeletal Muscle Depletion Measured on Computed Tomography for Overall Survival in Patients with Non-Metastatic Breast Cancer.

Authors:  Jimi Huh; Bumhee Park; Heirim Lee; Young-Sil An; Yongsik Jung; Ji Young Kim; Doo Kyoung Kang; Kyung Won Kim; Tae Hee Kim
Journal:  J Breast Cancer       Date:  2020-01-07       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.